期刊
PEDIATRIC NEUROLOGY
卷 101, 期 -, 页码 43-46出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.pediatrneurol.2019.07.019
关键词
Dichlorphenamide; Adolescent; Child; Periodic paralysis; Muscle weakness; Rare disease; Hereditary; Channelopathy
资金
- Muscular Dystrophy Association
- U.S. Food and Drug Administration Orphan Drug Program [FD-R-000821]
- National Institutes of Health [M01-RR00044, M01-RR00585, M01-RR00034, M01-RR00064]
- National Institute of Neurological Disorders and Stroke
Background: Primary periodic paralyses are rare, hereditary skeletal muscle diseases characterized by episodic muscle weakness. Dichlorphenamide was effective and well tolerated in two studies, including one with adolescents. This analysis describes effects of dichlorphenamide among adolescents and adults. Methods: Patients with primary periodic paralyses in a double-blind, controlled, crossover study were randomized to dichlorphenamide or placebo for nine weeks, with a nine-week or longer between-treatment washout period. Attack rate and severity-weighted attack rate during the final eight weeks of each treatment phase were calculated for adolescents and adults separately. Results: Seven adolescents (10 to <= 17 years) and 66 adults were enrolled; five of seven adolescents were evaluable for efficacy and six for safety. Dichlorphenamide total daily dosing among adolescents was 50 mg (n = 1) or 100 mg (n = 5), and in adults was 105.7 mg (mean; n = 61). In adolescents, the median decrease from baseline in frequency of weekly attacks was greater with dichlorphenamide (-0.96) than with placebo (-0.57), similar to findings in adults (dichlorphenamide, -0.83; placebo, -0.24). Severity-weighted attack frequency was likewise reduced more with dichlorphenamide than with placebo in adolescents and adults. The most common adverse event with dichlorphenamide in adolescents was skin rash (two of six [33%]). In adults, numbness was the most common adverse event (26 of 54 [48%]); skin rash occurred less frequently (10 of 54 [19%]). Conclusions: Dichlorphenamide was comparably effective and tolerated among a small number of adolescents as well as adults, although types of adverse events differed between groups. (C) 2019 The Authors. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据